Celcuity Beats Q1 Loss Estimates, Bolstering Financial Outlook Ahead of Key Drug Launch
CELC has more than doubled off its 52-week low of $9.51 on elevated volume (2.6× avg).
Summary
Celcuity reported a smaller-than-expected Q1 loss, with adjusted EPS of -$0.86 significantly beating the consensus estimate of -$1.05, and adjusted net loss of -$46.80 million also surpassing expectations. This positive financial update follows a series of highly impactful news earlier this month, including positive topline results from its Phase 3 VIKTORIA-1 trial for gedatolisib and the FDA granting Priority Review with a PDUFA date of July 17, 2026. The earnings beat, combined with the company's expectation that its cash and investments will finance operations through 2027, provides a stronger financial foundation as Celcuity prepares for the potential Q3 2026 FDA approval and commercial launch of its key breast cancer treatment. Traders will monitor the upcoming FDA decision and the company's commercialization strategy.
At the time of this announcement, CELC was trading at $129.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $9.51 to $151.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.